Urological complications after COVID 19 vaccine according to age, sex and manufacturer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Sung Ryul | - |
dc.contributor.author | Kim, Kwang Taek | - |
dc.contributor.author | Park, Eunju | - |
dc.contributor.author | Pyun, Jong Hyun | - |
dc.contributor.author | Kim, Jae Heon | - |
dc.contributor.author | Chung, Benjamin I. | - |
dc.date.accessioned | 2023-08-30T00:40:26Z | - |
dc.date.available | 2023-08-30T00:40:26Z | - |
dc.date.created | 2023-07-21 | - |
dc.date.issued | 2023-08 | - |
dc.identifier.issn | 0724-4983 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89007 | - |
dc.description.abstract | ObjectivesTo examine the effects of age, sex, and type of COVID-19 vaccine on urological complications after vaccination with COVID-19.Materials and methodsWe used the Vaccine Adverse Event Reporting System (VAERS) data from December 2020 to August 2022 to analyze urological symptoms post-vaccination adverse events (AEs) associated with COVID-19 vaccines authorized for the U.S. population. We collected AEs after 1-2 dose vaccination in VAERS, but not those after an additional booster shot. Age was divided into three groups (< 18 years, 18-64 years, and > 64 years), and compared incidence of AEs after vaccination with either mRNA vaccine (mRNA-1273, Moderna; and BNT162b2, Pfizer-BioNTech) or a viral vector vaccine (JNJ-78436735, Janssen/Johnson and Johnson) as reported in VAERS data.ResultsCumulative incidence rates (CIRs) of LUTS, voiding symptom, storage symptom, infection, and hematuria were 0.057, 0.282, 0.223, 1.245, and 0.214, respectively. By gender, CIRs OF LUTS, storage symptom, and infection were statistically significantly higher in women, whereas CIRs of voiding symptom and hematuria were statistically significantly higher in men. CIRs of AEs per 100,000 in age groups of < 18 years, 18-64 years, and > 64 years were 0.353, 1.403, and 4.067, respectively. All AE types except for voiding symptom displayed the highest CIRs in the Moderna vaccine group.ConclusionsBased on an updated analysis of available data, the prevalence of urologic complications following administration of COVID-19 vaccines is low. However, specific urologic complications such as gross hematuria are not low in incidence. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | WORLD JOURNAL OF UROLOGY | - |
dc.title | Urological complications after COVID 19 vaccine according to age, sex and manufacturer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 001021350300002 | - |
dc.identifier.doi | 10.1007/s00345-023-04481-1 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF UROLOGY, v.41, no.8, pp.2255 - 2263 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85163883452 | - |
dc.citation.endPage | 2263 | - |
dc.citation.startPage | 2255 | - |
dc.citation.title | WORLD JOURNAL OF UROLOGY | - |
dc.citation.volume | 41 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Kim, Kwang Taek | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Vaccination | - |
dc.subject.keywordAuthor | Urologic symptoms | - |
dc.subject.keywordAuthor | Urologic side effects | - |
dc.subject.keywordPlus | HEMATURIA | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.